AI Portfolio Summary
In 2025 Q4, Sarissa Capital Management LP maintained a portfolio of 9 distinct positions. The most significant new addition to the portfolio was BIOHAVEN LTD, which now represents 2.60% of the total fund value. They heavily accumulated shares in AMARIN CORP PLC, increasing their position by 34.7%. The fund also reduced its exposure to CYTOKINETICS INC by 32.6%.
Total Positions
9
Quarter
2025 Q4
Top Holding
INVA (25.3%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-9 of 9
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
INVA
INNOVIVA INC
|
Healthcare | 25.25% | 28.49% |
#1
Prev: #1
|
7.0 | no change | no change |
P
S
|
2,816,022 | $56,292,280 | 2016 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IRWD
IRONWOOD PHARMA...
|
Healthcare | 24.07% | 11.56% |
#2
2
Prev: #4
|
6.5 | no change | no change |
P
S
|
15,919,435 | $53,648,496 | 2017 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NBIX
NEUROCRINE BIOS...
|
Healthcare | 19.29% | 23.59% |
#3
1
Prev: #2
|
6.0 | no change | no change |
P
S
|
303,151 | $42,995,906 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 11.30% | 17.93% |
#4
1
Prev: #3
|
4.5 | -192,000 | -32.6% |
P
S
|
396,357 | $25,184,524 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AMRN
AMARIN CORP PLC
|
Healthcare | 10.48% | 11.28% |
#5
Prev: #5
|
7.0 | 430,868 | 34.7% |
P
S
|
1,673,395 | $23,352,227 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LNTH
LANTHEUS HLDGS ...
|
Healthcare | 5.42% | 5.16% |
#6
Prev: #6
|
3.2 | no change | no change |
P
S
|
181,450 | $12,075,498 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BHVN
BIOHAVEN LTD
|
Healthcare | 2.60% | — |
#7
Prev: #—
|
4.5 | 513,184 | no change |
NEW
|
513,184 | $5,793,847 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
REGN
REGENERON PHARM...
|
Healthcare | 1.45% | 1.31% |
#8
1
Prev: #7
|
1.6 | no change | no change |
P
S
|
4,190 | $3,234,135 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VOR
VOR BIOPHARMA I...
|
Healthcare | 0.15% | 0.69% |
#9
1
Prev: #8
|
1.1 | no change | no change |
P
S
|
25,399 | $332,219 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-9 of 9 holdings